SCHEMBL4619797

SCHEMBL4619797

CCCOC(C(=O)N(C)CC1C2CNCC21)(c1ccccc1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 4/20 0.43
DRD3 P35462 4/20 0.43
HTR2C P28335 2/20 0.43
MLNR O43193 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HTR2A P28223 1/20 0.43
HRH1 P35367 1/20 0.43
OPRK1 P41145 1/20 0.43
HTR2B P41595 1/20 0.43
SLC6A3 Q01959 1/20 0.43
KCNH2 Q12809 1/20 0.43
CACNA1C Q13936 1/20 0.43
SSTR4 P31391 3/20 0.38
CYP3A4 P08684 3/20 0.34
CYP2D6 P10635 3/20 0.34
LMNA P02545 4/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4620288 0.87 SSTR4 (0.40) OPRM1DRD3HTR2CSSTR4DRD2
SCHEMBL4619684 0.81 BCHE (0.43) OPRM1DRD3HTR2CMLNRCHRM2
SCHEMBL4619862 0.80 SSTR4 (0.46) OPRM1DRD3HTR2CCHRM2CHRM1
SCHEMBL30741229 0.80 SSTR4 (0.43) OPRM1DRD3HTR2CCHRM2CHRM1
SCHEMBL4619386 0.79 HTR2C (0.45) OPRM1DRD3HTR2CMLNRCHRM2
SCHEMBL4620821 0.79 CHRM2 (0.50) OPRM1DRD3HTR2CMLNRCHRM2
SCHEMBL4617994 0.73 SSTR4 (0.41) OPRM1DRD3HTR2CCHRM2CHRM1
SCHEMBL4619013 0.71 LMNA (0.41) HTR2CSLC6A3KCNH2SSTR4CYP3A4
SCHEMBL4619098 0.69 ALPL (0.36) KCNH2SSTR4RAB9ANPSR1SLC6A9
SCHEMBL2443032 0.69 CHRM2 (0.54) OPRM1DRD3HTR2CMLNRCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US claimed
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP claimed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO claimed
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed
EP-1888525-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0]HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS Ranbaxy Laboratories Limited (IN) 2008-02-20 EP disclosed
WO-2006117754-A1 3,6-DISUBSTITUTED AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319043-A1 3,6-Disubstituted Azabicyclo (3.1.0) Hexane Derivatives as Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 OPRM1 111/4885DRD3 392/4885HTR2C 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.